9.4 C
Glasgow
Wednesday, April 1, 2026
spot_img

More News

Researchers move closer to preventing pandemics

admin -
Researchers have developed an AI tool that can help determine whether unfamiliar bacteria carry genetic features linked to disease....

Copper overload kills cancer cells

Jim Cornall -
Cuproptosis was discovered in 2022. It was a previously unknown type of cell death caused by an excess of...

Lyme disease vaccine shows strong efficacy in phase 3 trial

Jim Cornall -
Pfizer Inc. and Valneva SE have announced topline results from the phase 3 VALOR (Vaccine Against Lyme for Outdoor...

FDA approves pill for plaque psoriasis

Jim Cornall -
Johnson & Johnson has announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE (icotrokinra), an...

Crossbow Therapeutics raises $77m to treat cancer

Jim Cornall -
Crossbow Therapeutics, Inc. has raised $77m in a Series B financing that will support the completion of the CROSSCHECK-001...

Base to Base biotech podcast 52: Ketamine for depression, and a new company in the kidney disease space

Jim Cornall -
On this week’s episode, we chat with Hans Eriksson, chief medical officer (CMO) of HMNC Brain Health, about ketamine...

Excalipoint Therapeutics launches with $68.7m to develop T-Cell engager therapies

Jim Cornall -
Excalipoint Therapeutics has announced an oversubscribed $68.7m seed financing round to support advancement of its proprietary technology platforms and...

FDA clearance for refractory gout treatment

Jim Cornall -
Innorna has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application...

Earendil Labs raises $787m to scale AI-driven biologics discovery and development

Jim Cornall -
Earendil Labs has raised $787m in financing rounds. The funding will accelerate Earendil Labs' AI-driven R&D platform, expand its...

Researchers design drug capable of reversing cognitive decline in Alzheimer’s disease

Jim Cornall -
A team from the University of Barcelona has designed and validated in animal models a compound with a pioneering...

Shingles vaccine cuts risk of serious cardiac events

Jim Cornall -
People with heart disease who received a shingles vaccine had nearly half the rate of serious cardiac events a...

Initial data suggest favourable safety profile for Alzheimer’s drug

Jim Cornall -
Priavoid GmbH has announced promising initial safety data from its ongoing phase 2 trial (PRImus-AD) evaluating its lead candidate,...

Positive results from second-line metastatic breast cancer trial

Jim Cornall -
Pfizer Inc. has announced positive topline results from the randomised phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with...

Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer

Jim Cornall -
Outrun Therapeutics, a biotech developing protein stabilising therapeutics identified by its proprietary XL discovery platform, has selected its lead...

Fast Track Designation for HAE siRNA therapy

Jim Cornall -
Argo Biopharmaceutical Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation...

‘Molecule Manifesto’ pinpoints key pathways to $1.1tn biotech economy

Jim Cornall -
Advanced Biotech for Sustainability (AB4S), a cross-sector coalition committed to unlocking the full environmental potential of advanced biotechnology, published...

New mechanism driving breast cancer progression

Jim Cornall -
A research group led by Cecilia Sahlgren at Åbo Akademi University in Finland and the InFLAMES Research Flagship has...

Mutation strength in a single gene shapes tumour behaviour

Jim Cornall -
Cancer is often thought of as a single disease. Yet even tumours that arise in the same organ can...

Base to Base biotech podcast 51: Ovarian cancer, blue crayfish, and stopping brittle bone disease  

Jim Cornall -
On this week’s episode, we chat with Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and director...

EDPB and EDPS support harmonisation of clinical trials under European Biotech Act

Jim Cornall -
The European Data Protection Board (EDPB) and the European Data Protection Supervisor (EDPS) have adopted a Joint Opinion on...

IND clearance for focal epilepsy cell therapy

Jim Cornall -
Unixell Biotech’s UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media